Letybo vs. Jeuveau: How Two Newer-Generation Botulinum Toxins Compare in 2026

Letybo and Jeuveau are the two most prominent newer-generation alternatives to Botox on the U.S. cosmetic market. Both dose 1:1 against Botox, both target the same dynamic frown lines, and both compete on price with the long-standing market leader. Jeuveau has been FDA-approved for glabellar lines since February 2019 and is marketed as “Newtox.” Letybo, the dominant neurotoxin in South Korea for a decade, only received its U.S. cosmetic approval in February 2024.

This guide walks through the meaningful clinical, dosing, and cost differences based on current FDA labels, the BLESS phase-3 program for Letybo, and the EV-001/002 trials for Jeuveau. It is written by a clinic that carries Letybo but not Jeuveau, so the disclosure at the bottom is explicit about who fits which product best.

What Letybo and Jeuveau Actually Are

Both products are purified type A botulinum toxin for cosmetic use. Both block acetylcholine release at the neuromuscular junction, relaxing the muscle and softening the dynamic line above it. The mechanism is the same as Botox, Dysport, Daxxify, and Xeomin — what differs is the manufacturer, the purification process, and the formulation’s accessory proteins.

• Letybo (letibotulinumtoxinA-wlbg) — manufactured by Hugel America. FDA-approved for cosmetic glabellar lines in February 2024. It is the #1 prescribed botulinum toxin in South Korea and has been used internationally for over a decade. The active toxin sits inside an approximately 900 kDa complex with human serum albumin as the stabilizer.
• Jeuveau (prabotulinumtoxinA-xvfs) — manufactured by Evolus. FDA-approved for cosmetic glabellar lines in February 2019. It was the first new neurotoxin specifically marketed for aesthetics-only use in the U.S., branded as “Newtox.” It also uses an approximately 900 kDa complex with human serum albumin (Evolus calls its purification method Hi-Pure).

Both share the same core architecture as Botox: a 900 kDa neurotoxin complex stabilized with human serum albumin. That similarity is why both dose 1:1 against Botox and why most clinicians treat them as functionally interchangeable when switching patients between products.

Onset: How Quickly Will You See Results?

Both products are studied at similar onset windows, and patients usually cannot tell them apart.

• Letybo onset: Most patients see softening at 2–3 days, with a median onset of approximately 2.8 days reported in the BLESS program. Peak effect lands around 14 days.
• Jeuveau onset: Most patients see softening at 2–3 days, with peak effect at 10–14 days.

Both are modestly faster than Botox’s 3–7 day window. For patients who want visible softening before an event, either is a reasonable choice. For routine quarterly maintenance, the day-or-two spread between them is essentially irrelevant.

Duration: How Long Will Results Last?

Duration is the area where marketing claims tend to outrun the data, so it is worth being precise here.

• Letybo: Median glabellar duration of 3–4 months in the BLESS phase-3 trials, with re-treatment intervals consistent with other 1:1 toxins.
• Jeuveau: Median glabellar duration of 3–4 months in the EV-001/002 trials, with comparable re-treatment intervals.

Neither has shown a clinically meaningful duration advantage over the other. If duration is your top priority, the longer-acting option to discuss is Daxxify, studied at a 6-month median in the SAKURA program.

Dosing and Unit Conversion

This is the easiest area in the entire neurotoxin landscape, because both products dose identically to each other and to Botox.

Per the FDA labels:

• Letybo for glabellar lines: 20 units total, divided across 5 injection sites (4 units each).
• Jeuveau for glabellar lines: 20 units total, divided across 5 injection sites (4 units each).

Both follow a 1:1 conversion ratio against Botox. If you were dosed 20 units of Botox last time, your injector typically uses 20 units of Letybo or Jeuveau this time, in the same five-point pattern. The labels note that units are not formally interchangeable, so a competent injector confirms total dose on the day — but the math is identical in routine glabellar use.

This contrasts with Dysport (2.5–3:1) or Daxxify (2:1), where switching requires recalculation. Letybo and Jeuveau are easier mental swaps.

Diffusion and Precision

Both have tight diffusion profiles similar to Botox; neither shows the broader spread pattern that distinguishes Dysport. In practice both are well-suited for focal targets like crow’s feet, lip flips, bunny lines, and chin treatment, both behave predictably in the glabellar complex without unwanted spread into the lower frontalis, and neither requires the dilution adjustments that some injectors make for broader-spread toxins. If you have done well on Botox in the past, both will feel familiar.

Cost: What You Will Actually Pay in 2026

Both products are priced as Botox alternatives, with a slight differential favoring Letybo on the per-unit side.

• Letybo: roughly $9–$15 per unit. A standard 20-unit glabellar treatment lands around $200–$300 in most U.S. markets.
• Jeuveau: roughly $8–$12 per unit, generally positioned at 20–30% less than Botox per unit. A standard 20-unit glabellar treatment lands around $200–$280.

For most patients the out-of-pocket math is comparable. Both products are meaningfully less expensive than Botox at the per-unit level, and because they dose 1:1 against Botox, those per-unit savings translate cleanly into per-treatment savings. If you have been paying $300+ for 20 units of Botox and your injector offers either Letybo or Jeuveau as a clinically equivalent option, you should expect a real price difference.

One pricing caveat: rewards programs differ. Evolus operates a Jeuveau-specific loyalty program (Evolus Rewards). Letybo is new enough to the U.S. market that its loyalty infrastructure is still developing. If you are price-optimizing across multiple treatments per year, ask your clinic which program they participate in.

Side Effects and Safety

The side effect profiles are essentially identical, because the mechanism and formulation architecture are nearly identical.

Most common adverse events in the registration trials for both products:

• Headache (3–9%)
• Injection-site reactions — mild bruising, redness, transient swelling (1–5%)
• Eyelid drooping (ptosis), typically under 1% in trained hands
• Brow asymmetry, usually correctable with a small touch-up at the 2-week mark

Both carry the standard FDA boxed warning about the theoretical possibility of distant toxin spread; at the doses used for cosmetic facial treatment, this has not been a clinically meaningful concern.

One distinct point worth flagging for patients who care about long-term immunogenicity: Letybo’s BLESS phase-3 program reported no neutralizing antibodies across the studied population, which the manufacturer highlights as a long-term safety signal. Jeuveau, like all complexed toxins, can in theory produce antibody formation over many cycles, though clinically meaningful resistance remains rare across all type A toxins. If antibody risk is your top concern, the strongest theoretical case is for Letybo on the published data, or for the “naked toxin” formulation Xeomin if your clinic carries it.

Who Is the Ideal Candidate for Each?

Letybo may be the better fit if:

• You want a Botox-equivalent with a published lack of neutralizing antibodies
• You are price-sensitive and your clinic prices Letybo at the lower end of the range
• You want a clean 1:1 swap from Botox without recalculating units

Jeuveau may be the better fit if:

• Your clinic carries Jeuveau and you want Evolus Rewards loyalty pricing
• You want a name-brand Botox alternative with multiple years of U.S. clinical experience
• You have responded well to Jeuveau previously

Can You Switch Between Letybo and Jeuveau?

Yes. Because both use 1:1 dosing against Botox, switching is one of the simpler product transitions in the category. A few practical notes:

• Tell your new injector which product you previously had, the dose, and roughly when.
• You cannot mix the two in the same area in the same session.
• Switching brands does not reduce the baseline risk of antibody formation.
• Most patients report no perceptible difference swapping between Letybo, Jeuveau, and Botox session to session — all three sit in the same 900 kDa, 1:1-dosed family.